Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for VTE Prophylaxis in Transplant-Eligible Newly Diagnosed Multiple Myeloma Receiving VTD
2017-004592-31Phase 2Terminated
- Sponsor
- Health Research Institute Hospital La Fe
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apixaban in multiple myeloma (MM), sponsored by Health Research Institute Hospital La Fe. Primary endpoint: Feasibility of apixaban for VTE prophylaxis during VTD induction. Started Apr 2018; status: terminated.
02
Drugs
apixaban
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-004592-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004592-31.